Scholarlink

Purpose <p>Immunotherapy has become the standard first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC). This study aims to explore the impact of discontinuation of immunotherapy within 1 year on survival prognosis in patients with R/M NPC.</p> Materials and methods <p>We retrospectively collected the clinical characteristics, treatment regimens and hematological biomarkers of 114 patients with first-line R/M NPC in our unit. The patients were divided into two groups: discontinuation group with a duration of immunotherapy ≤ 12&#xa0;months and continuation group with a duration of immunotherapy &gt; 12&#xa0;months. The Kaplan–Meier method was used to validate the effect of duration of immunotherapy on overall survival (OS) and progression-free survival (PFS). Univariate and multivariate Cox regression analyses were conducted on duration of immunotherapy for OS.</p> Results <p>The median follow-up time was 25&#xa0;months. The median PFS for the continuation group was 39&#xa0;months, significantly better than the 24&#xa0;months observed in the discontinuation group (p = 0.0042). The continued group also significantly extended patient OS (p = 0.00048), though the median OS for both groups had not yet reached the endpoint. The 2-year OS rate of the discontinued group was 33.3%, while that of the discontinued group was 59.4%. Duration of immunotherapy ≤ 12&#xa0;months was an independent risk factor for OS in univariate Cox analysis (HR = 5.881 95%CI 1.931–17.917, p = 0.002) and multivariate Cox analysis (HR = 9.01 95%CI 1.924–42.192, p = 0.005).</p> Conclusions <p>The duration of immunotherapy &gt; 12&#xa0;months is associated with better OS in patients with first-line R/M NPC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Discontinuation of immunotherapy and its effect on prognosis in recurrent or metastatic nasopharyngeal carcinoma patients: a retrospective analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月18日

查看全文
  • Yingpeng Peng,
  • Xi Chu,
  • Dasong Zha,
  • Linghan Meng,
  • Jijin Yao,
  • Tianze Liu,
  • Qiaodan Liu,
  • Xiwei Xu,
  • Siyang Wang,
  • Mingyuan Chen,
  • Rui You,
  • Youping Liu

摘要

Purpose

Immunotherapy has become the standard first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC). This study aims to explore the impact of discontinuation of immunotherapy within 1 year on survival prognosis in patients with R/M NPC.

Materials and methods

We retrospectively collected the clinical characteristics, treatment regimens and hematological biomarkers of 114 patients with first-line R/M NPC in our unit. The patients were divided into two groups: discontinuation group with a duration of immunotherapy ≤ 12 months and continuation group with a duration of immunotherapy > 12 months. The Kaplan–Meier method was used to validate the effect of duration of immunotherapy on overall survival (OS) and progression-free survival (PFS). Univariate and multivariate Cox regression analyses were conducted on duration of immunotherapy for OS.

Results

The median follow-up time was 25 months. The median PFS for the continuation group was 39 months, significantly better than the 24 months observed in the discontinuation group (p = 0.0042). The continued group also significantly extended patient OS (p = 0.00048), though the median OS for both groups had not yet reached the endpoint. The 2-year OS rate of the discontinued group was 33.3%, while that of the discontinued group was 59.4%. Duration of immunotherapy ≤ 12 months was an independent risk factor for OS in univariate Cox analysis (HR = 5.881 95%CI 1.931–17.917, p = 0.002) and multivariate Cox analysis (HR = 9.01 95%CI 1.924–42.192, p = 0.005).

Conclusions

The duration of immunotherapy > 12 months is associated with better OS in patients with first-line R/M NPC.